Compare AbbVie Inc (ABBV) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Alphabet Inc Class A — how do they compare? AbbVie Inc trades at $246.8 (market cap $441.94B), while Alphabet Inc Class A trades at $343.49 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 9.5× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | GOOGL | |
|---|---|---|
Market Cap | $441.94B | $4.20T |
Sector | Health | Media |
52-Week High | $263.58 | $402.62 |
52-Week Low | $197.38 | $199.32 |
Enterprise Value | $506.19B | $4.09T |
Dividend Yield | 2.77% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Alphabet (GOOGL) trades at $357.52, up 0.91% today, with a bullish technical signal from moving averages and strong support at $354. The stock shows robust fundamentals, with revenue growing from $350.0B in 2024 to $402.8B in 2025 (SEC filings, 2025), net income margin expanding to 32.8%, and consistent earnings beats. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube price increases (Reuters, 2026-04-10).
Outlook remains positive with an 85% analyst buy rating and $426.28 consensus price target (MarketBeat, 2026-04-11), though risks include antitrust scrutiny and tech sector volatility. Earnings growth and AI integration are key catalysts for upside, while competition and regulatory pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
